1
|
Beal KM, Bandara KR, Ali SR, Sonak RG, Barnes MR, Scarcelli JJ, Zhang L. The impact of expression vector position on transgene transcription allows for rational expression vector design in a targeted integration system. Biotechnol J 2023; 18:e2300038. [PMID: 37272404 DOI: 10.1002/biot.202300038] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2023] [Revised: 05/09/2023] [Accepted: 05/31/2023] [Indexed: 06/06/2023]
Abstract
Site-specific integration (SSI) technology has emerged as an effective approach by the pharmaceutical industry for the development of recombinant Chinese hamster ovary (CHO) cell lines. While SSI systems have been demonstrated to be effective for the development of CHO cell lines, they can be limiting in terms of both transgene expression and in the case of multi-specifics, the ability to generate the correct product of interest. To maximize the performance of Pfizer's dual SSI expression system for expressing monoclonal and multi-specific antibodies, we used a novel approach to investigate the positional effect of transgenes within expression vectors by engineering nucleotide polymorphisms (NP)s to use as biomarkers to track the level of transcript output from each expression vector position. We observed differences in transcript level for two different transgenes across all four expression vector positions interrogated. We then applied these learnings to rationally design expression vectors for six different mAbs and a multi-specific antibody. We showed enhanced productivity and optimal product quality when compared to a conventional expression vector topology. The learnings gained here can potentially aid in the determination of optimal vector topologies for several IgG-like multi-specific formats.
Collapse
Affiliation(s)
- Kathryn M Beal
- Cell Line Development, Bioprocess R&D, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA
| | - Kalpanie R Bandara
- Cell Line Development, Bioprocess R&D, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA
| | - Syed R Ali
- Cell Line Development, Bioprocess R&D, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA
| | - Renuka G Sonak
- Cell Line Development, Bioprocess R&D, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA
| | - Michael R Barnes
- Cell Line Development, Bioprocess R&D, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA
| | - John J Scarcelli
- Cell Line Development, Bioprocess R&D, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA
| | - Lin Zhang
- Cell Line Development, Bioprocess R&D, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA
| |
Collapse
|
2
|
Wang Y, Quan Q, Gleason C, Yu H, Peng L, Kang Y, Jiang L, Wu K, Pan J, Bao M, Zhu Q, Yi M, Fang M, Zheng Y, Qiu L, Xu B, Li X, Song J, Sun J, Zhang Z, Su Z, Lin J, Xie Y, Xu A, Song X, Huang C, Shen Z, Wang L, Song J. Accelerating the speed of innovative anti-tumor drugs to first-in-human trials incorporating key de-risk strategies. MAbs 2023; 15:2292305. [PMID: 38095560 DOI: 10.1080/19420862.2023.2292305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2023] [Accepted: 12/04/2023] [Indexed: 12/18/2023] Open
Abstract
Pharmaceutical companies have recently focused on accelerating the timeline for initiating first-in-human (FIH) trials to allow quick assessment of biologic drugs. For example, a stable cell pool can be used to produce materials for the toxicology (Tox) study, reducing time to the clinic by 4-5 months. During the coronavirus disease 2019 (COVID-19) pandemic, the anti-COVID drugs timeline from DNA transfection to the clinical stage was decreased to 6 months using a stable pool to generate a clinical drug substrate (DS) with limited stability, virus clearance, and Tox study package. However, a lean chemistry, manufacturing, and controls (CMC) package raises safety and comparability risks and may leave extra work in the late-stage development and commercialization phase. In addition, whether these accelerated COVID-19 drug development strategies can be applied to non-COVID projects and established as a standard practice in biologics development is uncertain. Here, we present a case study of a novel anti-tumor drug in which application of "fast-to-FIH" approaches in combination with BeiGene's de-risk strategy achieved successful delivery of a complete CMC package within 10 months. A comprehensive comparability study demonstrated that the DS generated from a stable pool and a single-cell-derived master cell bank were highly comparable with regards to process performance, product quality, and potency. This accomplishment can be a blueprint for non-COVID drug programs that approach the pace of drug development during the pandemic, with no adverse impact on the safety, quality, and late-stage development of biologics.
Collapse
Affiliation(s)
- Yuqi Wang
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Quan Quan
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Camille Gleason
- Department of Regulatory Affairs CMC, BeiGene USA, Inc, San Mateo, CA, USA
| | - Helin Yu
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Lujia Peng
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Yanshen Kang
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Ling Jiang
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Kailun Wu
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Jie Pan
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Moxiyele Bao
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Qing Zhu
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Meiqi Yi
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Ming Fang
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Yue Zheng
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Ling Qiu
- Department of Technical Operation and Manufacturing, BeiGene (Guangzhou) Co. Ltd, Guangzhou, China
| | - Bin Xu
- Department of Technical Operation and Manufacturing, BeiGene (Guangzhou) Co. Ltd, Guangzhou, China
| | - Xiang Li
- Department of Technical Operation and Manufacturing, BeiGene (Guangzhou) Co. Ltd, Guangzhou, China
| | - Jinfeng Song
- Department of Technical Operation and Manufacturing, BeiGene (Guangzhou) Co. Ltd, Guangzhou, China
| | - Jiamu Sun
- Department of Regulatory Affairs CMC, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Zheng Zhang
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Zijun Su
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Jara Lin
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Yuanyuan Xie
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - April Xu
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Xiling Song
- Department of Regulatory Affairs CMC, BeiGene USA, Inc, San Mateo, CA, USA
| | - Chichi Huang
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Zhirong Shen
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Lai Wang
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Jing Song
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| |
Collapse
|
3
|
Tevelev B, Chambers A, Ghosh S, Zhang Y, Marzili L, Rouse JC, Han S, Moffat M, Scarcelli JJ. A genetic off-target event in a site-specific integration cell line expressing monoclonal antibody has no impact on commercial suitability. Biotechnol Prog 2022; 39:e3320. [PMID: 36545889 DOI: 10.1002/btpr.3320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 12/09/2022] [Accepted: 12/17/2022] [Indexed: 12/24/2022]
Abstract
Site-specific integration (SSI) cell line systems are gaining popularity for biotherapeutic development and production. Despite the proven advantages for these expression hosts, the SSI system is still susceptible to rare off-target events and potential vector rearrangements. Here we describe the development process of an SSI cell line for production of an IgG1 monoclonal antibody (mAb-086). During cell line generational studies to assess suitability of clone C10 for commercial purposes, restriction fragment lengths of genomic DNA harboring the light chain (LC) were not in agreement with the predicted size. We first confirmed that the SSI landing-pad achieved occupancy of the desired expression plasmid. Additional investigation revealed that random integration had occurred, resulting in the acquisition of a partial copy of the LC and a full-length copy of the heavy chain (HC) at a different locus in the host genome. This off-target event had no impact on the genotypic consistency and phenotypic stability of the cell line, the production process, or the drug substance product quality. Given the genetic, phenotypic, and process consistency of the cell line, clone C10 was deemed suitable as a manufacturing cell line.
Collapse
Affiliation(s)
- Barbara Tevelev
- Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA
| | - Andre Chambers
- Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Chesterfield, Missouri, USA
| | - Swap Ghosh
- Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Chesterfield, Missouri, USA
| | - Ying Zhang
- Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA
| | - Lisa Marzili
- Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA
| | - Jason C Rouse
- Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA
| | - Shu Han
- Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA
| | - Mark Moffat
- Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Chesterfield, Missouri, USA
| | - John J Scarcelli
- Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA
| |
Collapse
|
4
|
Oliviero C, Hinz SC, Bogen JP, Kornmann H, Hock B, Kolmar H, Hagens G. Generation of a Host Cell line containing a MAR-rich landing pad for site-specific integration and expression of transgenes. Biotechnol Prog 2022; 38:e3254. [PMID: 35396920 PMCID: PMC9539524 DOI: 10.1002/btpr.3254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2022] [Revised: 03/22/2022] [Accepted: 03/31/2022] [Indexed: 11/10/2022]
Abstract
In recent years, targeted gene integration (TI) has been introduced as a strategy for the generation of recombinant mammalian cell lines for the production of biotherapeutics. Besides reducing the immense heterogeneity within a pool of recombinant transfectants, TI also aims at shortening the duration of the current cell line development process. Here we describe the generation of a host cell line carrying Matrix‐Attachment Region (MAR)‐rich landing pads (LPs), which allow for the simultaneous and site‐specific integration of multiple genes of interest (GOIs). We show that several copies of each chicken lysozyme 5'MAR‐based LP containing either BxB1 wild type or mutated recombination sites, integrated at one random chromosomal locus of the host cell genome. We further demonstrate that these LP‐containing host cell lines can be used for the site‐specific integration of several GOIs and thus, generation of transgene‐expressing stable recombinant clones. Transgene expression was shown by site‐specific integration of heavy and light chain genes coding for a monospecific antibody (msAb) as well as for a bi‐specific antibody (bsAb). The genetic stability of the herein described LP‐based recombinant clones expressing msAb or bsAb was demonstrated by cultivating the recombinant clones and measuring antibody titers over 85 generations. We conclude that the host cell containing multiple copies of MAR‐rich landing pads can be successfully used for stable expression of one or several GOIs.
Collapse
Affiliation(s)
- Claudia Oliviero
- Institute of Life Technology, Haute Ecole d'Ingénierie HES-SO Valais Wallis, Rue de l'Industrie 19, CH-1950 Sion, Switzerland
| | - Steffen C Hinz
- Institute of Life Technology, Haute Ecole d'Ingénierie HES-SO Valais Wallis, Rue de l'Industrie 19, CH-1950 Sion, Switzerland
| | - Jan P Bogen
- Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Alarich-Weiss-Strasse 4, D-64287, Darmstadt, Germany
| | - Henri Kornmann
- Ferring Biologics Innovation Center, Route de la Corniche 8, CH-1066, Epalinges, Switzerland
| | - Björn Hock
- Ferring Biologics Innovation Center, Route de la Corniche 8, CH-1066, Epalinges, Switzerland.,SwissThera SA, Route de la Corniche 4, CH-1066, Epalinges, Switzerland
| | - Harald Kolmar
- Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Alarich-Weiss-Strasse 4, D-64287, Darmstadt, Germany
| | - Gerrit Hagens
- Institute of Life Technology, Haute Ecole d'Ingénierie HES-SO Valais Wallis, Rue de l'Industrie 19, CH-1950 Sion, Switzerland
| |
Collapse
|